Noblesville, Indiana-based Nexxt Spine LLC has announced the commercial launch of its Lordotic TLIF (transforaminal lumbar interbody fusion) Oblique interbody implant.
Novel Lordotic TLIF Oblique Interbody Implant Launched
1 min read Premium comments
#lumbarspineSecondary#nexxtspine#sagittalbalance
According to the company, this 3D-printed implant is part of the NEXXT MATRIXX family of products which means that it is a porous titanium cage designed to encourage organic cellular healing.
“Our surgeon network asked and we answered,” explains Nexxt Spine President, Andy Elsbury. “Collaborating with our surgeon partners on development is one of the greatest perks of manufacturing our own products. Nexxt Spine is continuously committed to increasing our portfolio of topnotch options to serve each unique surgeon and ultimately cater to the individual needs of patients.”
Elsbury told OTW, “Surgeons have become hooked on the Next Matrixx technology and the clinical outcomes it upholds. Requests come in daily for additional SKUs and iterations of our industry recognized 3D-printed titanium implants. The Lordotic TLIF Oblique was no exception. Born from a surgeon desire, Nexxt Spine delivered. Our engineers and manufacturing staff are perpetually working to add to our portfolio and keep up with demand.”
“The Lordotic TLIF Oblique provides a solution for the restoration and maintenance of disc height with the purpose of achieving sagittal balance in the lumbar spine. The cage offers a 6° lordosis angle in a selection of footprints to accommodate varying vertebral anatomy.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.